WJ 47156
Alternative Names: JS-125; WJ-47156Latest Information Update: 29 Sep 2024
At a glance
- Originator Shanghai Junshi Biosciences; Wigen Biomedicine
- Class Antineoplastics
- Mechanism of Action HDAC1 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 26 Aug 2024 Shanghai Junshi Bioscience plans a phase I trial for Solid tumours (Late-stage disease, Monotherapy, Combination therapy) in China (PO, Tablet) (NCT06571422, JS125-001-I)
- 09 Jul 2024 Preclinical trials in Solid tumours in China (PO), prior to July 2024
- 09 Jul 2024 National Medical Products Administration (NMPA) China approves IND application for WJ 47156 in Solid tumours